AMI Cardiogenic Shock

Clinical Evidence

Best Practice Protocols Include <sup>1-4</sup>

  • Identify CS early and Impella pre-PCI < 90 minutes
  • Aggressive down-titration of inotropes
  • Identify RV dysfunction early and support
  • Identify inadequate LV support and escalate
  • Systematic use of RHC to guide therapy

81% Survival at 30 Days in a Multi-Center, Multi-Society Study of Impella®-Supported AMI Cardiogenic Shock Patients

Junya Ako, MD, presents data from 593 consecutive patients with AMI cardiogenic shock (AMICS) supported with Impella heart pumps at 109 centers in Japan between October 2017 (when Impella heart pump was introduced in Japan) through January 2020. 

Impella Clinical Evidence has Established Safety and Effectiveness and Validated Best Practices

RECOVER IV Randomized Controlled Trial

Upcoming trial to assess whether Impella pre-PCI is superior to PCI without Impella in patients with AMI cardiogenic shock.

The Procedure

Learn more about femoral access explant techniques and other best practices.

References

  1. Tehrani, B. et al. (2019). J Am Coll Cardiol, 73(13), 1659–1669.
  2. O’Neill, W., et al. (2020). TCT Connect.
  3. Basir, B., et al. (2021). SCAI Scientific Sessions.
  4. Ako, J. (2022). TCT. AMICS with Impella-only Support.

NPS-1187